New drugs for the treatment of experimental alcoholism.
This article presents a current overview of the efforts to suppress pharmacologically the craving, dependence, or other factors associated with the self-selection of alcohol in an experimental animal. The contemporary status of the pharmacotherapy of experimental alcoholism similarly is described for different animal models of alcohol drinking. An evaluation is presented of several classes of drug for their efficacy in ameliorating the volitional ingestion of alcohol in the presence of an alternative fluid. Currently, two main experimental animal models of alcoholism are being used in this endeavor: (a) genetic lines or substrains of high alcohol preferring or high drinking rats; and (b) strains of nondrinking or low alcohol preferring rats which are induced chemically to prefer alcohol. Because of technical, methodological, and other issues surrounding the procedures used to assess the efficacy of a drug in reducing alcohol intake, several of the newer findings remain controversial. For example, serious side effects on the intake of food, caloric regulation, motor activity, or other functions would preclude the clinical utility of the drug. However, several drugs which affect monoaminergic neurons as well as opioid systems in the brain now seem to offer promise as agents which do possess clinical benefits. Two of these drugs, FG5606 (amperozide) and FG 5893 are essentially "antialcoholic" or anticraving and are without any significant side effects on cerebral mechanisms responsible for hunger, caloric intake, motor activity, or other physiological process. Amperozide, a 5-HT2 receptor antagonist with dopamine releasing properties, is particularly notable because of its irreversible nature in attenuating alcohol preference for months after its administration. It is concluded that future pharmacological research on presently available and newly developed compounds will provide exciting opportunities to the clinician who can utilize a particular drug as an adjunctive tool in the therapeutic treatment of the alcoholic individual.
Myers
R D
RD
Department of Pharmacology, School of Medicine, East Carolina University, Greenville, NC 27858.
D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D004195:Disease Models, Animal; D009292:Narcotic Antagonists; D009539:Nicotinic Acids / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D016713:Ritanserin / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000188:drug therapy
D009292:Narcotic Antagonists; D009539:Nicotinic Acids; D010879:Piperazines; C049058:amperozide; D016713:Ritanserin; C081594:FG 5893